Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emend Risk Program To Ensure Prescribers Understand Approved Indication

Executive Summary

Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications

You may also be interested in...



Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche

Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS

Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche

Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS

Merck Discontinues Substance P Depression Compound After Failed Trial

Merck is abandoning its efforts to develop the substance P antagonist aprepitant (MK-0869) for treatment of depression

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel